VHL and Thrombocytopenia: However, distinctly to Nav‐Gal, DT2216 has not been designed for targeting senescent cells, but for reducing thrombocytopenia (as platelets are characterized by poor VHL E3 ligase expression) while maintaining anti‐cancer properties.